Details for Patent: 8,629,171

Which drugs does patent 8,629,171 protect, and when does it expire?

Patent 8,629,171 protects DAKLINZA and is included in one NDA.

This patent has twenty-five patent family members in twenty countries.

Summary for Patent: 8,629,171

Title:	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
Abstract:	The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well as methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form.
Inventor(s):	Soojin Kim, Qi Gao, Fukang Yang
Assignee:	Bristol Myers Squibb Co
Application Number:	US12/175,104
Patent Claim Types: see list of patent claims	Use; Composition;

error: insufficient information

Drugs Protected by US Patent 8,629,171

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-001	Jul 24, 2015		DISCN	Yes	No	8,629,171		Y	Y		METHOD OF INHIBITING HEPATITIS C VIRUS
Bristol-myers Squibb	DAKLINZA	daclatasvir dihydrochloride	TABLET;ORAL	206843-002	Jul 24, 2015		DISCN	Yes	No	8,629,171		Y	Y		METHOD OF INHIBITING HEPATITIS C VIRUS

International Family Members for US Patent 8,629,171

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	070016
Argentina	104566
Australia	2008284100